{"url_path":"/sec/bioa/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1709941/0001193125-26-213466-index.html","accession_number":"0001193125-26-213466","cik":"0001709941","ticker":"BIOA","issuer_name":"BioAge Labs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1709941/0001193125-26-213466-index.html","primary_entity_key":"0001709941","primary_entity_name":"BioAge Labs, Inc."},"word_count":45,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDuring the fiscal quarter ended March 31, 2026, none of the Company’s directors or officers adopted or terminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.\n\n76"}